NASDAQ:HRMY

Harmony Biosciences Competitors

$28.40
+0.12 (+0.42 %)
(As of 04/16/2021 10:49 AM ET)
Add
Compare
Today's Range
$27.83
Now: $28.40
$28.93
50-Day Range
$27.56
MA: $31.36
$37.15
52-Week Range
$26.51
Now: $28.40
$52.74
Volume1,253 shs
Average Volume126,942 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Harmony Biosciences (NASDAQ:HRMY) Vs. IONS, SRPT, ALLK, BPMC, PRGO, and SDGR

Should you be buying HRMY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Harmony Biosciences, including Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), and Schrödinger (SDGR).

Harmony Biosciences (NASDAQ:HRMY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Harmony Biosciences and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences00303.00
Ionis Pharmaceuticals27602.27

Harmony Biosciences presently has a consensus price target of $51.6667, suggesting a potential upside of 81.92%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 41.14%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Ionis Pharmaceuticals.

Earnings and Valuation

This table compares Harmony Biosciences and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
Ionis Pharmaceuticals$1.12 billion5.15$303.26 million$2.0819.73

Ionis Pharmaceuticals has higher revenue and earnings than Harmony Biosciences.

Profitability

This table compares Harmony Biosciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
Ionis Pharmaceuticals7.82%6.57%3.39%

Insider & Institutional Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Harmony Biosciences on 7 of the 9 factors compared between the two stocks.

Sarepta Therapeutics (NASDAQ:SRPT) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Earnings and Valuation

This table compares Sarepta Therapeutics and Harmony Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million14.92$-715,080,000.00($9.71)-7.37
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Sarepta Therapeutics.

Insider & Institutional Ownership

89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sarepta Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Harmony BiosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Sarepta Therapeutics and Harmony Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191302.52
Harmony Biosciences00303.00

Sarepta Therapeutics currently has a consensus target price of $150.4762, suggesting a potential upside of 110.40%. Harmony Biosciences has a consensus target price of $51.6667, suggesting a potential upside of 81.92%. Given Sarepta Therapeutics' higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Harmony Biosciences.

Summary

Sarepta Therapeutics beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Harmony Biosciences and Allakos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
AllakosN/AN/A$-85,370,000.00($1.89)-55.73

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Harmony Biosciences and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences00303.00
Allakos00403.00

Harmony Biosciences currently has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Allakos has a consensus target price of $181.50, indicating a potential upside of 72.32%. Given Harmony Biosciences' higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Allakos.

Institutional & Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Harmony Biosciences and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
AllakosN/A-29.18%-27.70%

Blueprint Medicines (NASDAQ:BPMC) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Blueprint Medicines and Harmony Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million83.61$-347,690,000.00($7.27)-13.20
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Blueprint Medicines.

Profitability

This table compares Blueprint Medicines and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Harmony BiosciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Blueprint Medicines and Harmony Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
Harmony Biosciences00303.00

Blueprint Medicines currently has a consensus target price of $112.40, indicating a potential upside of 17.14%. Harmony Biosciences has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Harmony Biosciences is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Harmony Biosciences on 7 of the 10 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Profitability

This table compares Perrigo and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Harmony BiosciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Perrigo and Harmony Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Harmony Biosciences00303.00

Perrigo presently has a consensus target price of $52.00, indicating a potential upside of 25.36%. Harmony Biosciences has a consensus target price of $51.6667, indicating a potential upside of 81.92%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Perrigo.

Earnings & Valuation

This table compares Perrigo and Harmony Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.15$146.10 million$4.0310.29
Harmony BiosciencesN/AN/AN/AN/AN/A

Perrigo has higher revenue and earnings than Harmony Biosciences.

Insider & Institutional Ownership

82.7% of Perrigo shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Perrigo beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.

Harmony Biosciences (NASDAQ:HRMY) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Analyst Ratings

This is a summary of recent recommendations for Harmony Biosciences and Schrödinger, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Harmony Biosciences00303.00
Schrödinger01302.75

Harmony Biosciences currently has a consensus target price of $51.6667, suggesting a potential upside of 81.92%. Schrödinger has a consensus target price of $85.50, suggesting a potential upside of 9.36%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Schrödinger.

Valuation and Earnings

This table compares Harmony Biosciences and Schrödinger's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony BiosciencesN/AN/AN/AN/AN/A
Schrödinger$85.54 million63.99$-24,570,000.00N/AN/A

Harmony Biosciences has higher earnings, but lower revenue than Schrödinger.

Profitability

This table compares Harmony Biosciences and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Harmony BiosciencesN/AN/AN/A
Schrödinger-19.92%-7.25%-5.33%

Institutional and Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 41.3% of Schrödinger shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Harmony Biosciences beats Schrödinger on 6 of the 7 factors compared between the two stocks.


Harmony Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03+1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.52+1.6%$5.77 billion$380.83 million-9.15Analyst Report
Allakos logo
ALLK
Allakos
1.7$105.33+2.7%$5.74 billionN/A-38.44Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95+0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48+0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18+0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95+0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56+1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06+1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08+1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06+2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28+1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83+2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74+4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99+2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11+1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40+1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07+1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37+0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23+3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65+0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57+0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88+5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27+1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22+6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43+1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18+4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50+2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28+3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93+0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89+4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96+0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33+2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10+2.4%$2.06 billionN/A0.00Insider Selling
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$123.42+2.6%$2.03 billionN/A-11.15
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.07+4.0%$2.01 billion$410,000.00-5.88Analyst Report
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.52+2.2%$2.00 billion$103.54 million-19.19Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$60.11+3.8%$2.00 billionN/A-25.58Increase in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.